ctnnbl1 Antibody

What is CTNNBL1 and what are its primary cellular functions?

CTNNBL1 (catenin-β-like 1) is a widely expressed, highly conserved 62 kDa nuclear protein that contains an armadillo motif domain. Despite exhibiting no detectable primary sequence homology to karyopherin α, it functions as a novel NLS-binding protein with selective binding specificity . CTNNBL1 plays crucial roles in:

• Association with Prp19-containing RNA-splicing complexes through interaction with the CDC5L component

• Interaction with Prp31, another U4/U6.U5 tri-snRNP-associated splicing factor, through its NLS

• Binding to the antibody-diversifying enzyme AID (Activation-induced deaminase), which is essential for proper antibody diversification

This single-copy gene is conserved from fission yeast to humans, suggesting fundamental importance in cellular processes across eukaryotes . CTNNBL1-deficient mice die during mid-gestation, highlighting its developmental necessity, while CTNNBL1-deficient mouse primary B cells and yeast demonstrate delayed exit from quiescence .

What is the structural composition of CTNNBL1 protein?

Crystal structure analysis of human CTNNBL1 reveals a distinctive architecture that differs significantly from its closest homologue, karyopherin-α. The CTNNBL1 protein comprises three major structural domains :

• A HEAT-like domain (which includes a nuclear export signal)

• A central armadillo domain

• A coiled-coil C-terminal domain

The protein's central region contains an abbreviated armadillo domain that serves as a multifunctional interaction surface. Unlike karyopherin-α, CTNNBL1 shows unique structural features that explain its distinct NLS-binding specificity . The full-length human CTNNBL1 protein sequence is 563 amino acids, with a calculated molecular weight of approximately 65 kDa .

What tissue distribution patterns does CTNNBL1 exhibit?

CTNNBL1 is widely expressed throughout the human body but demonstrates variable expression levels across different tissues. According to expression studies, the highest concentration levels are found in :

• Skeletal muscle

• Placenta

• Heart

• Spleen

• Testis

• Thyroid

This broad distribution pattern suggests that CTNNBL1 performs fundamental cellular functions rather than tissue-specific roles, consistent with its involvement in universal processes like RNA splicing and nuclear protein transport .

What are the primary research applications for CTNNBL1 antibodies?

CTNNBL1 antibodies serve several critical research applications in molecular and cellular biology:

• Protein Detection by Western Blot: CTNNBL1 antibodies can effectively detect the native ~65 kDa protein in various cell lysates. Western blot analysis has been successfully performed on extracts from HepG2 cells using specific CTNNBL1 antibodies .

• Immunohistochemistry (IHC): For tissue localization studies, CTNNBL1 antibodies enable visualization of protein expression patterns in paraffin-embedded or frozen tissue sections .

• Immunofluorescence/Immunocytochemistry (IF/ICC): CTNNBL1 antibodies can be used to study the subcellular localization and potential colocalization with interaction partners like CDC5L, Prp19, and AID .

• Co-immunoprecipitation Assays: These antibodies have been successfully employed to validate protein-protein interactions between CTNNBL1 and its binding partners, including components of the spliceosome and AID .

• Investigating Splice Factor Association: CTNNBL1 antibodies are valuable tools for examining associations with Prp19-containing complexes and other splicing factors .

What methodological considerations should be addressed when using CTNNBL1 antibodies for pull-down assays?

When conducting pull-down assays with CTNNBL1 antibodies, researchers should consider several methodological factors:

• Protein Expression and Purification: For recombinant His-CTNNBL1 and truncated His-CTNNBL1(Δ1–76) proteins, effective purification requires a multi-step approach:

  • Initial purification using nickel-nitrilotriacetic acid column chromatography

  • Elution with a 0–500 mM imidazole gradient

  • Further purification by anion exchange at pH 8.0 on a Q column

  • Final gel filtration on Superdex 75

• GST Pull-Down Protocol:

  • Pre-incubate glutathione-Sepharose (25 μl/reaction) with GST-tagged protein (1 hour, 4°C)

  • Wash thoroughly to remove unbound protein

  • Incubate with cell lysate (~500 μl from 293T cells) to capture interaction partners

• Antibody Selection: For optimal results, select antibodies based on intended applications:

  • For detection of endogenous CDC5L and Prp19, monoclonal antibodies are recommended

  • Endogenous CTNNBL1 from 293T cells can be detected using anti-CTNNBL1 antiserum

  • Recombinant His-CTNNBL1 detection is more effective with monoclonal anti-CTNNBL1 antibodies

• Negative Controls: Always include appropriate negative controls to validate specific interactions and minimize false-positive results .

How can researchers optimize CTNNBL1 antibody usage for Western blot applications?

Optimal use of CTNNBL1 antibodies in Western blot applications requires careful consideration of several parameters:

• Sample Preparation:

  • Use freshly prepared protein extracts from relevant cell lines (e.g., HepG2 cells have shown good endogenous expression)

  • Include protease inhibitors during extraction to prevent degradation

  • Denature proteins thoroughly before loading for optimal epitope exposure

• Antibody Dilution:

  • The optimal working dilution should be determined empirically for each application and antibody lot

  • Start with the manufacturer's recommended dilution range and adjust as needed

  • Commercial polyclonal CTNNBL1 antibodies typically require optimization within specific dilution ranges for Western blot detection

• Detection Method:

  • Choose an appropriate secondary antibody compatible with your primary anti-CTNNBL1 antibody

  • Consider enhanced chemiluminescence (ECL) or fluorescence-based detection systems based on sensitivity requirements

  • For rabbit polyclonal CTNNBL1 antibodies, anti-rabbit secondary antibodies conjugated to HRP or fluorophores are suitable

• Expected Results:

  • The expected molecular weight of CTNNBL1 is approximately 65 kDa

  • Validate specificity by comparing observed band sizes with predicted molecular weights

How does CTNNBL1's NLS-binding mechanism differ from karyopherin α, and how can researchers investigate this distinction?

CTNNBL1 represents a novel class of NLS-binding proteins with distinct binding properties from the well-characterized karyopherin α family. Key differences and investigation approaches include:

Understanding these differences is crucial for researchers investigating nuclear transport mechanisms and protein-protein interactions in the context of RNA splicing and antibody diversification.

What evidence supports the role of CTNNBL1 in antibody diversification, and how can researchers investigate this function?

CTNNBL1 plays a significant role in antibody diversification through its interaction with AID (Activation-induced deaminase). The following evidence supports this function:

• Interaction Evidence:

  • Two-hybrid and co-immunoprecipitation assays have identified CTNNBL1 as an AID-specific interactor

  • The interaction is specific to AID among cytidine deaminases, suggesting functional significance

• Functional Impact:

  • AID mutants that disrupt CTNNBL1 interaction show severely diminished hypermutation and class switching abilities

  • Targeted inactivation of CTNNBL1 in DT40 B cells considerably reduces IgV diversification

• Research Approaches:

  • Researchers can use CTNNBL1 antibodies in co-immunoprecipitation experiments to pull down AID complexes

  • Mutagenesis studies targeting specific residues in both AID and CTNNBL1 can help map critical interaction interfaces

  • ChIP (Chromatin Immunoprecipitation) assays using CTNNBL1 antibodies may reveal association with immunoglobulin loci during active diversification

• Mechanistic Hypothesis:

  • CTNNBL1 may provide a mechanistic link between AID recruitment and target-gene transcription

  • The spliceosome association of CTNNBL1 suggests potential coupling between RNA processing and antibody diversification processes

What approaches can resolve contradictory experimental results when using CTNNBL1 antibodies?

When researchers encounter contradictory results with CTNNBL1 antibodies, several systematic troubleshooting approaches can help resolve discrepancies:

• Antibody Validation Strategies:

  • Perform side-by-side comparison of multiple antibody clones targeting different CTNNBL1 epitopes

  • Validate antibody specificity using CTNNBL1-knockout or knockdown systems

  • Confirm findings using complementary techniques (e.g., mass spectrometry)

• Technical Considerations:

  • Evaluate fixation and permeabilization methods that may affect epitope accessibility

  • Assess potential post-translational modifications that might interfere with antibody recognition

  • Consider the use of tagged CTNNBL1 constructs and anti-tag antibodies as alternative detection methods

• Experimental Design Controls:

  • Include both positive controls (cells/tissues known to express CTNNBL1) and negative controls

  • Perform peptide competition assays to confirm binding specificity

  • Consider isotype controls to rule out non-specific binding

• Data Integration Approach:

  • Combine multiple detection methods (Western blot, immunofluorescence, mass spectrometry)

  • Correlate protein detection with mRNA expression data

  • Compare results with published literature while accounting for methodological differences

How can researchers optimize immunoprecipitation protocols specifically for CTNNBL1 and its interaction partners?

Optimizing immunoprecipitation (IP) protocols for CTNNBL1 requires attention to several critical variables:

• Cell Lysis Conditions:

  • Since CTNNBL1 is a nuclear protein associated with splicing complexes, nuclear extraction protocols are preferable

  • Use gentle lysis buffers that preserve protein-protein interactions while effectively extracting nuclear proteins

  • Include appropriate protease and phosphatase inhibitors to prevent degradation and modification during extraction

• Antibody Selection and Immobilization:

  • For endogenous CTNNBL1 IP, use validated anti-CTNNBL1 antisera or monoclonal antibodies

  • For recombinant His-tagged CTNNBL1, anti-His antibodies may provide higher specificity

  • Consider pre-clearing lysates with protein A/G beads to reduce non-specific binding

  • Use the appropriate antibody-to-protein ratio (typically 1-5 μg antibody per 500 μl cell lysate)

• Washing Conditions:

  • Optimize salt concentration to balance between preserving specific interactions and reducing background

  • Consider detergent type and concentration based on interaction strength

  • The number and duration of washes should be empirically determined for each interaction pair

• Elution and Detection:

  • For co-IP, use Western blotting with specific antibodies against known interactors (CDC5L, Prp19, PLRG1, Prp31)

  • For discovery of novel interactors, mass spectrometry analysis of immunopurified complexes has proven effective

What are the optimal conditions for expressing and purifying recombinant CTNNBL1 for antibody validation and binding studies?

Based on published protocols, the following approach has been effective for CTNNBL1 expression and purification:

• Expression Systems:

  • E. coli expression systems have been successfully used for recombinant CTNNBL1 production

  • For selenomethionine-labeled protein, B834(DE3) cells provide good expression levels

  • Both full-length CTNNBL1 and N-terminally truncated versions (CTNNBL1Δ76) can be effectively expressed

• Purification Protocol:

  • Initial purification via nickel-nitrilotriacetic acid column binding

  • Gradient elution with 0–500 mM imidazole

  • Secondary purification by anion exchange chromatography at pH 8.0 using a Q column

  • Final polishing step using gel filtration on Superdex 75

• Buffer Optimization:

  • For crystallization, CTNNBL1 has been successfully maintained in 20 mM Hepes pH 7.5, 50 mM NaCl, 1 M DTT

  • Protein concentration of approximately 24 mg/ml has been achieved for structural studies

  • Storage buffers should include reducing agents to prevent oxidation of cysteine residues

• Quality Control Metrics:

  • Assess purity using SDS-PAGE (>95% purity recommended)

  • Verify identity by Western blot and/or mass spectrometry

  • Evaluate activity through binding assays with known interaction partners (CDC5L NLS3, Prp31 NLS)

How can researchers characterize the binding kinetics between CTNNBL1 and its NLS-containing partners?

Detailed characterization of CTNNBL1-NLS interactions requires quantitative biophysical techniques:

• Isothermal Titration Calorimetry (ITC):

  • ITC has successfully determined the binding parameters of CTNNBL1-NLS interactions

  • The direct binding of CDC5L NLS to the ARM domain of CTNNBL1 shows a stoichiometry of two CDC5L NLS3 peptides per CTNNBL1 molecule

  • Binding affinities (Kd values) of 0.11 μM and 4.1 μM have been measured for the two binding sites

  • This binding profile shows similarity to karyopherin α1 binding to SV40 T antigen NLS, though with distinct specificity

• Surface Plasmon Resonance (SPR):

  • SPR provides real-time kinetic measurements (ka, kd) not obtainable by ITC

  • Immobilize either CTNNBL1 or the NLS peptide on the sensor chip

  • Measure association and dissociation rates at different analyte concentrations

  • Extract binding constants and compare different NLS sequences

• Pull-Down Assays:

  • Glutathione-Sepharose beads pre-incubated with GST-tagged NLS proteins can effectively pull down CTNNBL1

  • Comparative pull-downs with different NLS constructs help establish binding preferences

• Fluorescence Anisotropy:

  • Label NLS peptides with appropriate fluorophores

  • Measure changes in anisotropy as a function of CTNNBL1 concentration

  • Determine binding constants through fitting to appropriate binding models

How might CTNNBL1 function connect RNA splicing with antibody diversification, and what experimental approaches could investigate this relationship?

The dual role of CTNNBL1 in both RNA splicing complexes and antibody diversification suggests intriguing mechanistic connections that researchers can explore:

• Mechanistic Hypothesis:

  • CTNNBL1 may serve as a bridge between transcription/splicing machinery and AID-mediated antibody diversification

  • Active transcription and splicing could create structural opportunities for AID targeting of immunoglobulin genes

  • CTNNBL1's NLS-binding activity might facilitate the nuclear localization and targeting of AID to appropriate genomic regions

• Experimental Approaches:

  • ChIP-seq experiments with antibodies against CTNNBL1, splicing factors, and AID to identify genomic co-localization

  • RNA immunoprecipitation to investigate whether CTNNBL1-AID complexes associate with specific transcripts

  • Analysis of splicing patterns in immunoglobulin genes in CTNNBL1-deficient cells

  • Proximity ligation assays to visualize CTNNBL1-AID-spliceosome interactions in situ

• Genetic Manipulation Strategies:

  • Structure-guided mutagenesis to create CTNNBL1 variants that selectively disrupt either splicing factor or AID interactions

  • CRISPR-based genome editing to modify endogenous CTNNBL1 in B cells

  • Rescue experiments in CTNNBL1-deficient DT40 cells with mutant forms of CTNNBL1

What insights does the crystal structure of CTNNBL1 provide for developing specific inhibitors or modulators of its function?

The crystal structure of CTNNBL1 offers several opportunities for rational design of modulators:

• Structural Features for Targeting:

  • The unique abbreviated armadillo domain presents a distinct surface from karyopherin-α

  • The coiled-coil C-terminal domain provides a potential protein-protein interaction interface

  • The HEAT-like domain containing a nuclear export signal offers another functional region for intervention

• NLS-Binding Pocket Analysis:

  • Structure-based mutagenesis has revealed that CTNNBL1's NLS binding differs from karyopherin-αs

  • This distinct binding mechanism offers opportunities for selective targeting without disrupting general nuclear import

  • Computational modeling of the binding pocket could guide small molecule design

• Structure-Based Approaches:

  • Virtual screening of compound libraries against the NLS-binding pocket

  • Peptide-based inhibitors mimicking high-affinity NLS sequences

  • Fragment-based drug discovery targeting specific surface features

• Validation Strategies:

  • In vitro binding assays to confirm compound interaction with recombinant CTNNBL1

  • Cellular assays measuring CTNNBL1-dependent processes like AID function

  • Structural confirmation of binding mode through co-crystallization or NMR studies